HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
18. November 2024 21:27 ET
|
HCW Biologics, Inc
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
18. November 2024 07:00 ET
|
HCW Biologics, Inc
HCW Biologics signed license agreement with WY Biotech
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
14. November 2024 16:40 ET
|
HCW Biologics, Inc
Press release for Q3 2024 business highlights and financial results
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
23. August 2024 16:30 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
14. August 2024 16:35 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
15. Mai 2024 16:39 ET
|
HCW Biologics, Inc
Earning release for Q1 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
01. April 2024 16:10 ET
|
HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
14. November 2023 07:00 ET
|
HCW Biologics, Inc
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
08. November 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
01. November 2023 07:30 ET
|
HCW Biologics, Inc
Masonic Cancer Center, University of Minnesota to Present Human Data Readout for HCW9218 Phase 1 Study at SITC 2023